At the same time, OVs therapy can regulate the expression of immune inhibitory factors, such as inducing tumor cells to produce interferon and other cytokines to down-regulate PD-L1 expression and the inhibitory capacity of CTLA-4, enhancing the recognition and killing of tumor cells by immune cells, and improving the sensitivity of lung cancer to OVs therapy (39, 55). The gene discussed is CD274; the disease is lung cancer.